Article thumbnail

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences

By Alexander Karl and Badrinath Konety

Abstract

Androgen deprivation therapy (ADT) has been the mainstay of palliative treatment in advanced and metastatic prostate cancer for many years. It is also increasingly being used in patients with localized disease. Here we review some recent trials that are providing information on its benefits and disadvantages in different circumstances

Topics: Review Article
Publisher: Medicine Reports Ltd
OAI identifier: oai:pubmedcentral.nih.gov:2920692
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). American Society of Clinical Oncology: Initialhormonalmanagementofandrogen-sensitivemetastatic, recurrent, or progressive prostate cancer:
  2. (2004). Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer.
  3. (2005). Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
  4. (2006). Cooperative Oncology Group study EST 3886: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol
  5. (2006). Faculty of 1000
  6. (2006). MD: Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev
  7. (2000). Melezinek I: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
  8. (2006). MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
  9. (1993). Noncancer deaths in white adult cancer patients.
  10. (2008). Oh WK: Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer
  11. (2007). PR: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
  12. (2002). PR: Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology
  13. (2002). Resilience Across the Lifespan.
  14. (1999). Spano G: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
  15. (2002). Systematic review and metaanalysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer
  16. (2007). TJ: Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev
  17. (2000). TJ: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med
  18. (2005). Zattoni F; European Association of Urology: EAU guidelines on prostate cancer. Eur Urol